Innovis Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Innovis Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,141	Closed	-$237K	–	178
2023 Q2	$237K	Buy	13,141 +82	+0.6%	+$1.3K	0.09%	140
2023 Q1	$164K	Buy	13,059 +78	+0.6%	+$1.14K	0.07%	151
2022 Q4	$190K	Buy	+12,981	New	+$215K	0.09%	138

Other funds holding TARS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Innovis Asset Management's TARS Position: Q3 2023 in Review

Innovis Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2023, closing a stake of 13,141 shares — an estimated $237K sold.

Innovis Asset Management first reported a position in TARS in Q4 2022 and held it in 3 quarters. The position peaked at $237K in Q2 2023. 105 funds tracked by Wall St. Rank hold TARS as of Q3 2023.

Innovis Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Innovis Asset Management sold 13,141 Tarsus Pharmaceuticals shares in Q3 2023, an estimated $237K.
Innovis Asset Management first reported a position in Tarsus Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Innovis Asset Management's Tarsus Pharmaceuticals position peaked at $237K in Q2 2023.
105 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.